ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PYXS vs SIGA // EV/EBITDA & P/E VALUATION

Pyxis Oncology Inc. (NASDAQ) VS. SIGA Technologies Inc. (NASDAQ) • 15-METRIC TALLY: PYXS 2 — SIGA 6
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PYXS VS. SIGA) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PYXS SIGA SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 82.80% 68.60% +14.20 PYXS /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 42.70% -77.70 SIGA /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — 4.8x — TIE /valuation <GO>
Free Cash Flow Yield — 19.03% — TIE /fcf-yield <GO>
Operating Margin -60.00% 25.10% -85.10 SIGA /operating-margins <GO>
Net Profit Margin -60.00% 24.60% -84.60 SIGA /net-margins <GO>
Revenue Growth (YoY) -14.20% -31.80% +17.60 PYXS /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 8.22 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 6/9 -3.00 SIGA /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 34.8 36.7 -1.88 SIGA /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 9.1x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $226.0M $228.5M -$2.5M SIGA /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PYXS REV SIGA REV PYXS GROSS % SIGA GROSS % PYXS FCF SIGA FCF
FY 2025 $13.9M $94.6M 82.8% 68.6% -$63.5M $43.5M
FY 2024 $16.1M $138.7M 97.1% 77.4% -$57.9M $48.8M
FY 2023 $0 $139.9M — — -$70.7M $94.8M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PYXS // BETA —
SIGA // BETA —